# Nereus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nereus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.nereuspharm.com
- Total disclosed funding: $142M
- Latest round: Series D (Feb 15, 2008)
- Investors on record: 20

## About

Nereus Pharmaceuticals is based in US and operates as a pharmaceutical company which engages in development and discovery of drug used in oncology, infectious diseases, and inflammation.

## Funding rounds

- Series D, Feb 15, 2008, $22M — Advent International, Alta Partners, Forward Ventures, InterWest Partners, HBM Partners, Red Abbey, Pacific Venture Group
- Series D, Aug 9, 2007, $31M — Advent International, Alta Partners, Forward Ventures, InterWest Partners, HBM Partners, Gimv, Astellas Venture Management, Pacific Venture Group, O-Bank, Roche Venture Fund, BankInvest
- Series D, Jun 4, 2007, $14M — Advent International, Alta Partners, Forward Ventures, InterWest Partners, HBM Partners, Novartis Venture Fund, Red Abbey, Pacific Venture Group, Societe Generale Capital Partenaires
- Series D, Feb 24, 2006, $18M — Advent International, Alta Partners, Forward Ventures, InterWest Partners, HBM Partners, Novartis Venture Fund, Gimv, Red Abbey, Pacific Venture Group, Sanofi-Synthelabo, Lotus Biosciences Ventures
- Series D, Jan 4, 2005, $24M — Advent International, Alta Partners, Forward Ventures, InterWest Partners, HBM Partners, Novartis Venture Fund, Gimv, Red Abbey, Pacific Venture Group, Sanofi-Synthelabo, Lotus Biosciences Ventures
- Series B, Jul 30, 2001, $24M — Alta Partners, Forward Ventures, Novartis Venture Fund, Gimv, Pacific Venture Group, China Development Bank Capital, Icon Ventures, Blue Dot Capital, Lotus Biosciences Ventures, Swiss 1st
- Series A, Apr 17, 2000, $8.6M — Alta Partners, Forward Ventures

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B, Series D
- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A, Series B, Series D
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series D
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B, Series D
- Pacific Venture Group (https://capitalatlas.ai/funds/pacific-venture-group) — Series B, Series D
- China Development Bank Capital — Series B
- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series B
- Blue Dot Capital — Series B
- Lotus Biosciences Ventures (https://capitalatlas.ai/funds/lotus-biosciences-ventures) — Series B, Series D
- Swiss 1st — Series B
- Advent International (https://capitalatlas.ai/funds/advent-international) — Series D
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series D
- Sanofi-Synthelabo — Series D
- Societe Generale Capital Partenaires (https://capitalatlas.ai/funds/societe-generale-capital-partenaires) — Series D
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series D
- O-Bank (https://capitalatlas.ai/funds/o-bank) — Series D
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series D
- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series D